Clinical trial

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545

Study summary

ClinicalTrials.gov

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AEG35156 Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2007-11-01

PhasePHASE1 / PHASE2

Conditions

Human Mammary Carcinomaunresolved

Interventions

AEG35156DRUG

Sponsors & collaborators

Aegera Therapeuticslead sponsor

Mapped research locations

DallasTexas, United States1 IndianapolisIndiana, United States1 DenverColorado, United States1 GreenvilleSouth Carolina, United States1 AlbanyNew York, United States1 DaytonOhio, United States1 NorfolkVirginia, United States1 TylerTexas, United States1 VancouverWashington, United States1 OcoeeFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00558545 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.